Suiseng Each 2 mL (dose) contains: Escherichia coli Fimbrial Adhesin F4ab F4ac F5 F6 %65% ER60 278% ER70 279% ER 50 >80% ER35 >55% ER 70 >35% ER25 >50% ER120 E. coli LT Enterotoxoid Clotridium perfringens (Type C) BToxoid Clostridium novyi (Type B) a Toxoid % ERx: Percentage of immunized rabbits with enzyme immunoassay response. Suspension for Injection (IM)

Country: Philippines

Language: English

Source: FDA (Food And Drug Administration)

Active ingredient:

Inactivated Escherichia coli Fimbrial Adhesin (F4ab, F4ac, F5 and F6) , Heat Labile (LT) Enterotoxoid , Clotridium perfringens (Type C) B Toxoid , Clostridium novyi (Type B) a Toxoid Vaccine (Vet.)

Available from:

HIPRA Philippines Inc.; Distributor: HIPRA Philippines Inc.

INN (International Name):

Inactivated Escherichia coli Fimbrial Adhesin (F4ab, F4ac, F5 and F6) + Heat Labile (LT) Enterotoxoid + Clotridium perfringens (Type C) B Toxoid + Clostridium novyi (Type B) a Toxoid Vaccine (Vet.)

Dosage:

Each 2 mL (dose) contains: Escherichia coli Fimbrial Adhesin F4ab F4ac F5 F6 %65% ER60 278% ER70 279% ER 50 >80% ER35 >55% ER 70 >35% ER25 >50% ER120 E. coli LT Enterotoxoid Clotridium perfringens (Type C) BToxoid Clostridium novyi (Type B) a Toxoid % ERx: Percentage of immunized rabbits with enzyme immunoassay response.

Pharmaceutical form:

Suspension for Injection (IM)

Units in package:

Type I Glass Vial x 20 mL, 50 mL and 100 mL with Rubber Stopper and Alu Cap (Box of l’s)

Manufactured by:

Laboratorios HIPRA, S.A., Spain

Authorization date:

2022-03-08